Changement de direction
Inspiration Healthcare Group plc
("Inspiration Healthcare", la "Société" ou le "Groupe")
Changement de direction
Strengthens Board with appointment of Roy Davis as Non-Executive Director and Chair Designate
Inspiration Healthcare Group plc (AIM: IHC), the global medical technology ("med tech") company pioneering best-in-class, specialist neonatal intensive care medical devices, announces the appointment of Gordon Roy Davis ("Roy") as a Non-Executive Director and successor to Mark Abrahams. Mark has been Chair of the Board since June 2015 following the reverse acquisition of Inditherm plc by Inspiration Healthcare Ltd. Roy will become a Non-Executive Director with effect from 25 January 2024 and Chair from 21 March 2024, when Mark Abrahams will step down from the Board of the Company. On joining the Board, he will be appointed to the Nominations Committee and will succeed Mark Abrahams as Chair of this Committee.
Roy brings a wealth of commercial experience in medical devices companies and has a proven track record of successfully scaling companies and delivering substantial value for shareholders. He has held leadership positions at a number of publicly quoted med tech companies, including CEO of Optos plc, a leading retinal imaging device manufacturer, from 2008 to 2016 until its sale to Nikon for £259m in February 2015. From 2007 to 2008, Roy was CEO of Gyrus Group plc, a leader in minimally invasive surgery and visualisation, until its acquisition by Olympus Corporation in 2008 for $1.9 billion.
He is currently Non-Executive Chair at LungLife AI plc, Foster and Freeman (the trading name of the Galton group of companies) and Rair Health Ltd and was until recently, Non-Executive Chair at Medica Group plc until its acquisition by IK Partners for £269 million earlier this year.
Mark Abrahams, Chair of Inspiration Healthcare said: "I am delighted to welcome Roy to the Board. He has all the necessary credentials to guide the Company through its next phase of development and I look forward to working with him during the transition to becoming Chair."
Neil Campbell, Chief Executive Officer of Inspiration Healthcare said: "Roy's proven commercial track record, experience and understanding of the med tech sector will be incredibly important to the Company as we continue to deliver our strategy. His knowledge of growing companies on the public markets will add significant value and makes him an ideal successor to Mark Abrahams. We look forward to capitalising on his expertise in our space."
Roy Davis, Chair designate of Inspiration Healthcare said: "I am delighted to be joining the Board of Inspiration Healthcare. The Company is addressing a critical need, providing innovative, lifesaving neonatal technologies and has the right products and expertise to deliver significant long-term sustainable growth. I look forward to working with Neil, the Executive team and the rest of the Board in executing the strategy and delivering the next stage of the Company's development."
In accordance with Schedule 2 (g) of the AIM Rules for Companies, Gordon Roy Davis (aged 67 years) holds/has held the following directorships/partnerships in the last five years:
Mandats/partenariats actuels | Mandats/partenariats antérieurs (cinq dernières années) |
LungLifeAI, Inc Rair Health Limited Galton Bidco Limited Galton Midco Limited Galton Topco Limited Galton Tradeco Limited | Groupe Medica plc Edinburgh Molecular Imaging Limited |
In addition to the above, Roy Davis was a director of C-Quential Limited until his resignation on 28 February 2001. The company entered into a creditors voluntary liquidation on 11 February 2002 and was subsequently dissolved on 18 August 2007.
Gordon Roy Davis holds no ordinary shares in the Company.
Il n'y a aucune autre divulgation à faire en vertu de l'annexe 2 (g) des règles AIM pour les entreprises.
Inspiration Healthcare Group plc | Téléphone : +44 (0) 330 175 0000 |
Neil Campbell, chef de la direction | |
Liberum (conseiller nommé et Broker) | Téléphone : +44 (0) 20 3100 2000 |
Phil Walker, Richard Lindley, Will King | |
| |
Walbrook PR Ltd (relations avec les médias et les investisseurs) | Téléphone : +44 (0) 20 7933 8780 |
Anna Dunphy/Stephanie Cuthbert/ Louis Ashe Jepson |
À propos d'Inspiration Santé
Inspiration Santé (AIM : IHC) conçoit, fabrique et commercialise une technologie médicale pionnière. Basée au Royaume-Uni, la société est spécialisée dans les dispositifs médicaux de soins intensifs néonatals, qui répondent à un besoin critique consistant à contribuer à sauver des vies et à améliorer les résultats des patients, dès les tout premiers souffles de vie.
La Société dispose d'un large portefeuille de ses propres produits et produits distribués complémentaires, destiné aux soins intensifs néonatals, conçu pour accompagner même les bébés les plus prématurés tout au long de leur séjour à l'hôpital. Ses produits de marque propre vont des équipements hautement sophistiqués tels que les ventilateurs pour le maintien des fonctions vitales jusqu'aux produits jetables à usage unique.
La Société vend ses produits directement aux hôpitaux et aux prestataires de soins de santé au Royaume-Uni et en Irlande, où elle distribue également une gamme de technologies médicales avancées pour la thérapie par perfusion. Dans le reste du monde, la Société dispose d'un réseau établi de partenaires de distribution dans le monde entier donnant accès à plus de 75 pays.
La société opère depuis son centre de fabrication et de technologie de classe mondiale à Croydon, dans le sud de Londres, et depuis ses installations de Hailsham, dans l'East Sussex.
Vous trouverez de plus amples informations sur Inspiration Healthcare sur https://inspirationhealthcaregroup.com/.
RNS peut utiliser votre adresse IP pour confirmer le respect des termes et conditions, pour analyser votre interaction avec les informations contenues dans cette communication et pour partager cette analyse de manière anonyme avec d'autres dans le cadre de nos services commerciaux. Pour plus d'informations sur la manière dont RNS et la Bourse de Londres utilisent les données personnelles que vous nous fournissez, veuillez consulter notre Politique de confidentialité.